anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Assessment of the sentinel lymph node (SLN) in patients with early stage breast cancer is vital in selecting the appropriate surgical approach. However, the existing methods, including methylene blue and nuclides, possess low efficiency and effectiveness in mapping SLNs, and to a certain extent exert side effects during application. Indocyanine green (ICG), as a fluorescent dye, has been proved reliable usage in SLN detection by several other groups. In this paper, the investigators introduce a novel surgical navigation system to detect SLN with ICG. This system contains two charge-coupled devices (CCD) to simultaneously capture real-time color and fluorescent video images through two different bands. During surgery, surgeons only need to follow the fluorescence display. In addition, the system saves data automatically during surgery enabling surgeons to find the registration point easily according to image recognition algorithms. The investigators aim to show that the usage of our surgical navigation system with ICG to detect SLNs in breast cancer patients is technically feasible.
Ankylosing spondylitis (AS), primary sclerosing cholangitis (PSC), and autoimmune pancreatitis (AIP) are known as extraintestinal manifestations (EIMs) of ulcerative colitis (UC). A 74-year-old Japanese man visited our hospital because of white stool. He had been diagnosed with AS when he was 30 years old, and he was HLA-B27-positive. Based on various examination results, it was suspected that AIP had caused bile duct stricture. During the clinical course, he was diagnosed with UC and PSC. Then, AIP was diagnosed because he had localized pancreatic enlargement, irregular stenosis of the main pancreatic duct, PSC, and no tumor cells of pancreas. A patient with all four of these diseases, AS, AIP, PSC, and UC, is very rare. Therefore, we report a quite rare case with three EIMs (AS, PSC, and AIP) of UC.
The present invention discloses a tumor-relevant protein, a coding gene thereof and the application thereof. The tumor-relevant protein is a protein having one of the following amino acid residue sequences: SEQ ID No. 2 in a sequence table, and a protein which causes the amino acid residue sequence of the SEQ ID No. 2 in the sequence table to be replaced and/or deleted and/or added by one or a plurality of amino acid residues and is relevant to a tumor. Small interference RNA inhibiting the expression of the tumor-relevant protein is any one complementary double-strand RNA composed of the positive strands and the anti-sense strands having the following nucleotide sequences: a nucleotide sequence whose positive stands have a third sequence in the sequence table, a nucleotide sequence whose anti-sense stands have a fourth sequence in the sequence table, a nucleotide sequence whose positive stands have a fifth sequence in the sequence table, and a nucleotide sequence whose anti-sense stands have a sixth sequence in the sequence table. The present invention provides a new foundation for further studying the adjustment and control relationship of the tumor-relevant protein and NF-kappa B and developing new drugs for treating inflammation and tumors.
The disposable negative wound pressure device (PICO) will be used to cover the midline incision. The dressing is changed on POD3 and removed on POD7. Data are collected on POD3, POD7 and POD30.
Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux HD-C4 dialyzer. Following the third treatment, the subjects will be switched to the Polyflux 210H dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
PURPOSE: A method for delivery of biologically active organic molecules e.g. peptides or proteins into the cytoplasm and use thereof are provided. Therefore, oligolysine transducing domain and oligolysine cargo molecular complexation, oligolysine fusion protein and expression vector thereof can be used as an intracellular transmitter of effective physiologically active substances. CONSTITUTION: The transducing domain which is covalently attached to organic molecules is oligolysine which comprises 3 to 12 lysine residues. The oligolysine transducing domain-binding fusion protein is efficiently transducible into cytoplasm, and biologically active. The cargo molecular is oligonucleotide, peptide, protein, oligosaccharide or polysaccharide.
The present invention relates to a moisture powder pack. In a conventional case, it takes 10-20 minutes to use a mask sheet pack. On the other end, the moisture powder pack can create the same efficacy as if a user uses a mask pack since the user applies toner or lotion after applying powder. In addition, there is an effect of reducing a time. Accordingly, the moisture powder pack can solve the problem that too much time is consumed as a mask sheet has to be attached in a conventional case. That is, the present invention relates to a powder mask pack. The powder mask pack comprises: moisture powder which supplies moisture, and is provided in the form of powder to replenish moisture; a brush which is provided in the form of a brush used for color makeup so that the powder can be easily applied; and a container formed in an elongated cylinder shape to contain powder.
Spontaneous dorsal cord herniations are very rare, with only 3 reported cases published in the literature. We report a case of a 15-year-old girl, presenting with progressive symptoms of myelopathy, diagnosed with dorsal cord herniation. She was managed surgically. The herniated arachnoid forming the cyst wall was opened to find a dorsally herniated mass of the dorsal spinal cord. The dura was opened above and below the herniation and then around it to free the herniating nodule of the spinal cord. The nodule was not reducible and was partially amputated for biopsy, and to facilitate dural closure. The patient's post-operative course was uneventful with no fresh deficits. Lower limb weakness improved to 5/5 power with normal gait at 3 months follow-up. We speculate, after a literature review, that the dorsal cord herniation is a 'dorsal trans-dural appendage of the spinal cord' possibly resulting from (a) abnormal migration of neural crest cells during formation of dorsal meninges; or (b) abnormal differentiation of neural crest cells; or (c) abnormal signaling by the neural crest cells.
All patients received Zadaxin (1.6 mg subcutaneous injection, once a day) in the first 2 weeks, and changed frequency (1.6 mg subcutaneous injection, twice a week) in the successive 22 weeks. It is still recommended to continue treatment until the end of the study. All subjects were given HAART treatment throughout. In 4th week, 8th week, 12th week and 24th week, perform 4 follow-up and record the changes in CD4+ T cell count and proportion, CD8+ T cell count and proportion, proportions of T cell subsets, PBMC sjTREC, proportions of exhauseted T cell expressed PD-1 and Tim-3, and HIV viral load. During the process, safety assessment is performed, including adverse events, electrocardiogram and a series of laboratory tests (blood routine, liver and kidney function, etc.).
Treatment was performed with the SRT-Laser system (Medical Laser Center Lübeck, Germany), which consists of a Q-switched frequency doubled Nd:YLF laser (527nm), operating with a pulse repetition rate of 100 Hz. The pulse duration (full width at half maximum) was 1.7 µs. The laser energy was transmitted via fiber to a Lumenis slitlamp allowing the application of a fixed spot size diameter of 200 µm in air. A Mainster central field contact lens with a magnification of 1.05 was used for all irradiations. Per foot switch, 30 pulses are emitted, the pulse energy was chosen by the physician up to a maximum of 370 µJ. According to the treatment protocol, prior to each treatment 5 test shots with increasing energy were applied adjacent to the vessel arcades, in each patient in order to determine the appropriate pulse energy for treatment by recording the OA-value.
PROBLEM TO BE SOLVED: To decrease the body weight of a human in a safe effective manner by orally-administering a conjugated linoleic acid in a nutritionally effective amount. SOLUTION: The conjugated linoleic acid in a nutritionally effective amount is orally administered to decrease the body weight of a human. The above- mentioned nutritionally effective amount is preferably about 0.1-15 g per day. The above-mentioned con jugate linoleic acid is preferably cis-9, trans-11- octadecadienoic acid or the like. This compound is prescribed into tablets, capsules or the like, or offered as a supplement in variously prepared foods. According to the method, the body weight can be decreased without losing healthy nutritional elements and without requiring a person to refrain from taking a preference, differing from a restricted diet.
The symptoms and sequelae of sickle cell anaemia (SCA) are caused by the polymerization of deoxygenated sickle haemoglobin, and people with SCA may be uniquely susceptible to adverse outcomes from hypoxia and haemoglobin desaturation. We examined by oximetry adults (aged 18-45 years) with SCA presenting symptoms indicative of polysomnography, at a single institution, irrespective of treatment, for nocturnal hypoxaemia. Clinical labs and blood for in vitro assessments were taken upon enrolment and after 8-12 weeks of oxygen therapy or observation. Of 21 screened participants, nine (43%) had sufficient nocturnal hypoxaemia to warrant oxygen therapy (≥5 min at SpO2 ≤ 88%). Time spent at SpO2 ≤ 88% associated with age (p = 0.0092), annual hospitalizations (p = 0.0018) and anaemia (p = 0.0139), as well as plasma levels of TNFα (p = 0.0019) and IL-4 (p = 0.0147). Longitudinal analysis showed that WBC significantly decreased during the follow-up period in hypoxic individuals but not in non-hypoxic individuals (p = 0.0361 and p = 0.6969 respectively). Plasma levels of CCL2 and IL-1ra tended to increase, while levels of red blood cell reactive oxygen species tended to decrease with oxygen therapy. Overall, nocturnal hypoxaemia was common in this pilot study population and associated with plausible clinical comorbidities; oxygen therapy may decrease inflammation and oxidative damage in hypoxic individuals.
Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .
Adult patients with suspected or confirmed infection and who will be sampled for blood culture (a surrogate for suspected severe infection) will be recruited from three large emergency departments in a University hospital. Two blood samples will be collected: one for the analysis of matrix metalloproteinases, their inhibitor tissue inhibitor of metalloproteinase-1 (TIMP-1), FGF-21 and metabolomic analyses. Another blood sample is for the analysis of blood lactate. Clinical data will be collected to calculate quick SOFA (qSOFA), in order to test whether lactate and/or MMP-8 will improve the prognostic model if they are added to qSOFA. The primary outcome measure is the number of days alive without the need for ICU or high dependency unit treatment. The ability of MMP-8 to discriminate severe infection from uneventful course of the disease will be studied. The secondary aim is to study the metabolic changes in acutely ill patients with infection and compare these variables between survivors and non-survivors. The planned number of patients recruited is 924. During this study the feasibility of a bedside rapid analysis of MMP-8 will be tested in 30 patients and the results obtained using the rapid analyser compared with laboratory results obtained using ELISA.
Physical dependence, psychological dependence, and abuse haveoccurred. When chronic intoxication from prolonged use occurs, itusually involves ingestion of greater than recommended doses and ismanifested by ataxia, slurred speech, and vertigo. Therefore, carefulsupervision of dose and amounts prescribed is advised, as well asavoidance of prolonged administration, especially for alcoholics andother patients with a known propensity for taking excessive quantitiesof drugs.

Sudden withdrawal of the drug after prolonged and excessive use mayprecipitate recurrence of pre-existing symptoms such as anxiety,anorexia, insomnia, or withdrawal reactions such as vomiting, ataxia,tremors, muscle twitching, confusional states, hallucinosis, andrarely, convulsive seizures. Such seizures are more likely to occur inpersons with central nervous system damage or pre-existent or latentconvulsive disorders. Onset of withdrawal symptoms occurs usuallywithin 12 to 48 hours after discontinuation of meprobamate;symptoms usually cease within the next 12 to 48 hours.

When excessive dosage has continued for weeks or months, dosageshould be reduced gradually over a period of one or two weeks ratherthan abruptly stopped. Alternatively, a long-acting barbiturate may besubstituted, then gradually withdrawn.
The invention provides a amyotrophic lateral sclerosis prediction and prognosis evaluation system and a method for constructing a sALS prediction and prognosis evaluation model based on various proteins. The system comprises an input module, a prediction evaluation module and an output module. The input module is used for obtaining the content of various candidate ALS serum biomarkers. The prediction evaluation module is used for calculating and grading according to the sALS prediction and prognosis evaluation models based on various proteins, judging that amyotrophic lateral sclerosis is caused when the grading result is larger than or equal to a specific judgment threshold value, and judging that amyotrophic lateral sclerosis is not caused when the grading result is smaller than the specific judgment threshold value. And the output module is used for outputting the prediction evaluation result. After the technical scheme is adopted, the amyotrophic lateral sclerosis can be simply, quickly and accurately predicted and evaluated.
The invention belongs to the technical field of traditional Chinese medicines (TCMs) and provides a medicine used for treating chloasma, aiming to solve the problem of treating chloasma. The medicine is prepared from Chinese angelica, prepared rhizome of rehmannia, herba epimedii, Chinese yam, Indian bread, oriental waterplantain rhizome, amur corktree bark, chrysanthemum, tree peony root bark, asiatic cornelian cherry fruit, barbary wolfberry fruit, motherwort herb, safflower, peach kernels, common buried rubber, turmeric root tuber, radix astragali and atractylodes macrocephala according to a certain proportion. A preparation method of the medicine is characterized by comprising the following steps: after mixing the medicines, adding 600ml of water to a first dose to decoct the first dose until 200ml and adding 500ml of water to a second dose to decoct the second dose until 200ml. The medicine is taken on an empty stomach respectively in the morning and in the evening each day. In the TCM preparation, prepared rhizome of rehmannia, herba epimedii, Chinese yam, Indian bread, oriental waterplantain rhizome, tree peony root bark, asiatic cornelian cherry fruit and barbary wolfberry fruit have the function of nourishing the liver and the kidney; amur corktree bark, chrysanthemum and turmeric root tuber have the functions of soothing the liver to resolve depression and purging fire; Chinese angelica, motherwort herb, safflower, peach kernels and common buried rubber have the function of activating blood circulation to dissipate stasis; radix astragali and atractylodes macrocephala have the function of tonifying the spleen and qi. Through compatibility and synergy of the medicines, the medicine has good curative effects on chloasma.
Patients undergo cryoablation. If there are no significant postoperative complications, Serplulimab should be administered immediately. Cycles with Serplulimab repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
The palatine mucosa will be dried with a cotton ball 2\*2 and then 0,2 g of Emla cream will be applied for 3 minutes . During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
PURPOSE OF REVIEW: The prevalence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide, making it the leading cause of liver related morbidity and mortality. Currently, liver biopsy is the gold standard for assessing individuals with steatohepatitis and fibrosis. However, its invasiveness, sampling variability, and impracticality for large-scale screening has driven the search for non-invasive methods for early diagnosis and staging. In this review, we comprehensively summarise the evidence on the diagnostic performance and limitations of existing non-invasive serum biomarkers and scores in the diagnosis and evaluation of steatosis, steatohepatitis, and fibrosis.
RECENT FINDINGS: Several non-invasive serum biomarkers and scores have been developed over the last decade, although none has successfully been able to replace liver biopsy. The introduction of new NAFLD terminology, namely metabolic dysfunction-associated fatty liver disease (MAFLD) and more recently metabolic dysfunction-associated steatotic liver disease (MASLD), has initiated a debate on the interchangeability of these terminologies. Indeed, there is a need for more research on the variability of the performance of non-invasive serum biomarkers and scores across the diagnostic entities of NAFLD, MAFLD and MASLD. There remains a significant need for finding valid and reliable non-invasive methods for early diagnosis and assessment of steatohepatitis and fibrosis to facilitate prompt risk stratification and management to prevent disease progression and complications. Further exploration of the landscape of MASLD under the newly defined disease subtypes is warranted, with the need for more robust evidence to support the use of commonly used serum scores against the new MASLD criteria and validation of previously developed scores.
The present invention relates to the method for extracting and isolating active substances from umbu pulp ( Spondias tuberosa Arr. Camara ). Besides high acetylcholinesterase inhibitory activity, the active substances also exhibit powerful antioxidant activity. In view of their properties, the fractionated extract and the active principles obtained by the claimed method can be used in nutraceutical and/or functional foods or in cosmetics. In the form of foods, the active principles are used for the treatment of neurodegenerative diseases. In the form of cosmetics, the active principles are used against ageing.
Implant-associated infection (IAI) has become an intractable challenge in clinic. The healing of IAI is a complex physiological process involving a series of spatiotemporal connected events. However, existing titanium-based implants in clinic suffer from poor antibacterial effect and single function. Herein, a versatile surface platform based on the presentation of sequential function is developed. Fabrication of titania nanotubes and poly-γ-glutamic acid (γ-PGA) achieves the efficient incorporation of silver ions (Ag+) and the pH-sensitive release in response to acidic bone infection microenvironment. The optimized PGA/Ag platform exhibits satisfactory biocompatibility and converts macrophages from pro-inflammatory M1 to pro-healing M2 phenotype during the subsequent healing stage, which creates a beneficial osteoimmune microenvironment and promotes angio/osteogenesis. Furthermore, the PGA/Ag platform mediates osteoblast/osteoclast coupling through inhibiting CCL3/CCR1 signaling. These biological effects synergistically improve osseointegration under bacterial infection in vivo, matching the healing process of IAI. Overall, the novel integrated PGA/Ag surface platform proposed in this study fulfills function cascades under pathological state and shows great potential in IAI therapy.
There has been a great deal of discussion about mesh complications in urogynecology. During the following decade, vaginal mesh operations for pelvic organ prolapse increased exponentially all over the world, particularly in the United States. Once the complications started to increase, the publication of mesh-related complications on social and broadcast media and the increase of medico-legal claims the United States led to an extensive FDA (Food and Drug Administration) restriction on vaginal mesh procedures in 2013. On January 5, 2016, the FDA reclassified surgical mesh for transvaginal repair of the pelvic organ prolapse into class III, which require premarket approval. Finally, on April 16, 2019, the FDA ordered all manufacturers of urogynecological mesh intended for transvaginal repair to stop selling and distributing their products immediately. However, awareness of the other doctors in branches of medicine outside of gynecology and urology is unknown.
FIELD: medicine, biotechnology. SUBSTANCE: human abortion serum is diluted by 4-fold and mixed with affine resin containing antibodies raised to alpha-fetoprotein in concentration 1 g/l, not less. Liquid is decanted and resin is transferred in chromatography column. Alpha-fetoprotein is eluted from resin with 4 MgCl 2  solution, obtained solution is subjected for ultrafiltration and CaCl 2  and tris-OH are added up to final concentration 0.1 M and trypsin also. Solution is kept, subjected for ultrafiltration and alpha-fetoprotein concentrate is obtained with purity 90%, not below. Polysaccharide and physiological solution are added to the product followed by sterilization, ampoulation and drying. EFFECT: simplified method, decreased cost, high purity and quality of end product. 2 cl
Although Selective Serotonin Reuptake Inhibitors(SSRIs) and Cognitive Behavior Therapy (CBT) including Exposure and Response Prevention(ERP) are two kinds of the first line treatments for OCD(Obsessive-Compulsive Disorder) according to APA（American Psychological Association）guideline. Both of the treatments are effective, but few research has been done to find out who are more responsive to one treatment than the other. The aim of our research is to evaluate the efficiency of SSRIs ,ERP and the combination of the two therapies for OCD patients ,at the same time, to find out the biological and psychological predictors of treatment response in Chinese population.

This is a randomized, single-blind, cross-over design study.Approximately 60 patients will be randomized to SSRIs or ERP group. Neuropsychological assessment and fMRI(Functional Magnetic Resonance Imaging） will be performed at baseline,during the treatment and at the end of the study. The research has two period. In the first period(before week 8) ,the patients will have monotherapy. In the second period(after week 8), rates of improvement based on the YBOCS(Yale-Brown Obsessive Compulsive Scale) scores will be assessed. The patient will be considered responsive to treatment when he or she has a reduction in YBOCS score ≥ 35% of the score at the baseline.If the patient is responsive to the treatment that he or she has received at the first 8 weeks,he or she will continue to follow the previous treatment strategy.If not,the patient will have a combination of SSRIs and ERP treatment for another 8 weeks. The follow-up period will last up to 6 months.The result of the study will improve our knowledge about the efficacy of the two first line treatments .Also,it will help us to find out the predictors of the outcome of the two different kinds of treatments.Strategy of clinical treatment of OCD will be more individualized in the future.
Subjects in the GSK2586184 200 mg Arm will receive twice daily dose of GSK2586184 200 mg (1 x 200 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.